Minimal Residual Diseases (MRD): Hematology Journal Club 2
This journal club was a scientific-educational activity discussing data from BLAST trial, reflecting on the role of achieving and sustaining Minimal Residual Disease negativity status. The Role of Blinatumomab in managing Minimal Residual Disease (MRD) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).
One of its key goals was to share clinical experience on the use of Blinatumomab in MRD+ adult ALL patients.
Speaker: Sabir Hussain
Affiliations: Consultant Hematologist & Oncologists, Tawam Hospital, Al Ain, United Arab Emirates
This presentation was part of a scientific educational activity discussing data from BLAST trial, reflecting on the role of achieving and sustaining Minimal Residual Disease negativity status . The Role of Blinatumomab in managing Minimal Residual Disease (MRD) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).
Speaker: Mahmoud Marashi
Affiliations: Consultant Hematologist, Mediclinic City Hospital, , United Arab Emirates
This presentation was part of a scientific educational activity discussing data from BLAST trial, reflecting on the role of achieving and sustaining Minimal Residual Disease negativity status . The Role of Blinatumomab in managing Minimal Residual Disease (MRD) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).
Speaker: Hani Osman
Affiliations: Consultant Hematologist, Tawam Hospital, United Arab Emirates
This presentation was part of a scientific educational activity discussing data from BLAST trial, reflecting on the role of achieving and sustaining Minimal Residual Disease negativity status. The Role of Blinatumomab in managing Minimal Residual Disease (MRD) in B-Cell Acute Lymphoblastic Leukemia (B-ALL).
Panel Discussion including Mahmoud Marashi and Hani Osman.
